• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Acute myeloid leukemia
Cancer

KPNB1 targeting shows antileukemic effects

June 10, 2025
No Comments
Acute myeloid leukemia (AML) is the most prevalent hematological malignancy. Despite advances in the field, about 60% of patients with AML do not survive >5 years. It is an urgent need to identify novel therapeutic targets for managing AML.
Read More
Kidneys
Inflammatory

Novel STING antagonist shows robust anti-inflammatory activity

June 10, 2025
No Comments
Persistent activation of the stimulator of interferon genes (STING), resulting from aberrant metabolism or mutations in STING1, can lead to inflammatory damage and autoimmune diseases. Therefore, inhibiting STING activity may offer therapeutic potential for treating these disorders.
Read More
Neurology/psychiatric

Solve FSHD and Modalis collaborate on treatment for muscular dystrophy subtype

June 10, 2025
No Comments
Solve FSHD and Modalis Therapeutics Corp. have established a strategic collaboration to develop an innovative therapy for facioscapulohumeral muscular dystrophy (FSHD).
Read More
Gastrointestinal

Kv1.3 induces alcohol-related liver disease

June 10, 2025
No Comments
Researchers have investigated the role of the voltage-dependent potassium channel Kv1.3 in vivo in a murine model of ethanol-exposed alcohol-related liver disease (ALD).
Read More
Female hands holding heart on cardiogram
Cardiovascular

Nuevocor’s NVC-001 cleared to enter clinic for dilated cardiomyopathy

June 10, 2025
No Comments
Nuevocor Pte. Ltd. has obtained IND clearance by the FDA for NVC-001, an AAV-based gene therapy.
Read More
Dermatologic

Alys Pharmaceuticals submits CTA for ALY-301 for cold urticaria

June 10, 2025
No Comments
Alys Pharmaceuticals Inc. has submitted a clinical trial application (CTA) to Germany’s Paul-Ehrlich-Institut (PEI) to initiate a phase I/Ib study of ALY-301 in healthy volunteers and patients with cold urticaria, a subtype of chronic inducible urticaria.
Read More
Microscopic image showing histology of a glioblastoma multiforme
Cancer

Myosin Therapeutics’ MT-125 gains IND clearance for glioblastoma

June 10, 2025
No Comments
Myosin Therapeutics Inc. has obtained IND clearance by the FDA for MT-125. A phase I study will evaluate MT-125 in combination with standard-of-care radiation in patients with newly diagnosed IDH wild type, MGMT unmethylated glioblastoma.
Read More
Doctor pointing at liver
Gastrointestinal

First-in-class FABP/PPAR multiple modulator disclosed

June 10, 2025
No Comments
Researchers from Guangdong Pharmaceutical University and collaborators reported the discovery of [I], a novel FABP/PPAR multiple modulator aimed at the treatment of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a complex liver disease with limited treatment options.
Read More
Respiratory

Triple cyclin-dependent kinase targeting inhibits progressive fibrosis

June 10, 2025
No Comments
In progressive fibrotic diseases, which can occur in nearly all organs, myofibroblasts are activated to differentiate into proliferating fibroblastic cells that express genes that lead to deposition of extracellular matrix. The factors driving myofibroblast activation appear to be varied and complex, ranging from mechanical insults to inflammation, infection and cancer.
Read More

Free access to BioWorld coronavirus articles

June 9, 2025
The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:

Vaccines and therapeutics in development
Diagnostics with U.S. FDA emergency use authorization
Clinical trials of biopharma products affected by COVID-19
Read More
Previous 1 2 3 4 5 6 7 8 9 … 17750 17751 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2025.
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • The Nasdaq Stock Exchange headquarters in New York

    Omada, Caris arrivals continue med-tech IPO hot streak

    BioWorld MedTech
    Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe